Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
Changhoon Yoo, Milind Javle, Helena Verdaguer Mata, et al.
Hepatology (2023)
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Neutrophils in Cancer immunotherapy: friends or foes?
Xueqin Huang, Eugenie Nepovimová, Vojtěch Adam, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 32
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 24
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Emerging Therapies in Management of Cholangiocarcinoma
Jessica Speckart, Veronica Rasmusen, Zohray Talib, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 613-613
Open Access | Times Cited: 5
Neutrophil diversity and function in health and disease
F Zhang, Yidan Xia, Jiayang Su, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure
Michael J. Birrer, Guiling Li, Mayu Yunokawa, et al.
JAMA Oncology (2024) Vol. 10, Iss. 9, pp. 1204-1204
Open Access | Times Cited: 4
New systemic treatment options for advanced cholangiocarcinoma
Valentina Zanuso, Giulia Tesini, Elena Valenzi, et al.
Journal of Liver Cancer (2024) Vol. 24, Iss. 2, pp. 155-170
Open Access | Times Cited: 4
Advances in targeting tumor microenvironment for immunotherapy
Lugang Wang, Liubo Zhang, Zhen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Radiation-induced lung injury: from mechanism to prognosis and drug therapy
Sheng Wang, Duo Xu, Lingyan Xiao, et al.
Radiation Oncology (2025) Vol. 20, Iss. 1
Open Access
Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 879-879
Open Access | Times Cited: 3
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, et al.
Seminars in Liver Disease (2024) Vol. 44, Iss. 02, pp. 159-179
Open Access | Times Cited: 3
Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial
Chi‐Leung Chiang, Tai‐Chung Lam, James Chun Bong Li, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 40, pp. 100898-100898
Open Access | Times Cited: 5
Exploring Molecular Mechanisms in the Second-Line Treatment of Biliary Tract Malignant Tumors
QianLin Liu, Pengfei Zhang, Qiu Li
Discovery Medicine (2024) Vol. 36, Iss. 180, pp. 48-48
Open Access | Times Cited: 1
The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer
Guilherme Sacchi de Camargo Correia, Yujie Zhao, Rami Manochakian, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
Tarık Demır, Carolyn Moloney, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology (2024) Vol. 199, pp. 104388-104388
Closed Access | Times Cited: 1
Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
Xiaoli Wen, Gaosi Xu
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 545-556
Open Access | Times Cited: 1
Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer
Luohang Ni, Jianing Xu, Quanpeng Li, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 941-963
Open Access | Times Cited: 1
TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma
Sanjive Qazi, Vuong Trieu
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11221-11221
Open Access | Times Cited: 1
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials
Ana‐Marija Milenković‐Grišić, Nadia Terranova, Diane R. Mould, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 13, Iss. 1, pp. 143-153
Open Access | Times Cited: 4
TGF-β in tumor microenvironment, metabolism, and immunotherapy
Haotian Bai, Yisong Y. Wan
Elsevier eBooks (2024), pp. 53-93
Closed Access
A commentary on ‘Toxicities associated with immune checkpoint inhibitors: a systematic study’
Lin Guo, Xu Sun, Kai Kang, et al.
International Journal of Surgery (2024)
Open Access
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial
Do‐Youn Oh, Masafumi Ikeda, Choong‐kun Lee, et al.
Hepatology (2024)
Open Access
Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)
Makoto Ueno, C. Morizane, Masafumi Ikeda, et al.
ESMO Open (2024) Vol. 9, Iss. 10, pp. 103919-103919
Open Access
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial
Lixia Yi, Haoqi Pan, Zhouyu Ning, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top